Background Individuals with end-stage kidney disease (ESKD) on dialysis are vulnerable to contracting COVID-19 infection, with mortality as high as 31 % in this group. Population demographics in the UAE are dissimilar to many other countries and data on antibody responses to COVID-19 is also limited. The objective of this study was to describe the characteristics of patients who developed COVID-19, the impact of the screening strategy, and to assess the antibody response to a subset of dialysis patients. Methods We retrospectively examined the outcomes of COVID19 infection in all our haemodialysis patients, who were tested regularly for COVID 19, whether symptomatic or asymptomatic. In addition, IgG antibody serology was also performed to assess response to COVID-19 in a subset of patients. Results 152 (13 %) of 1180 dialysis patients developed COVID-19 during the study period from 1st of March to the 1st of July 2020. Of these 81 % were male, average age of 52​ years and 95 % were on in-centre haemodialysis. Family and community contact was most likely source of infection in most patients. Fever (49 %) and cough (48 %) were the most common presenting symptoms, when present. Comorbidities in infected individuals included hypertension (93 %), diabetes (49 %), ischaemic heart disease (30 %). The majority (68 %) developed mild disease, whilst 13 % required critical care. Combinations of drugs including hydroxychloroquine, favipiravir, lopinavir, ritonavir, camostat, tocilizumab and steroids were used based on local guidelines. The median time to viral clearance defined by two negative PCR tests was 15 days [IQR 6–25]. Overall mortality in our cohort was 9.2 %, but ICU mortality was 65 %. COVID-19 IgG antibody serology was performed in a subset (n = 87) but 26 % of PCR positive patients (n = 23) did not develop a significant antibody response. Conclusions Our study reports a lower mortality in this patient group compared with many published series. Asymptomatic PCR positivity was present in 40 %. Rapid isolation of positive patients may have contributed to the relative lack of spread of COVID-19 within our dialysis units. The lack of antibody response in a few patients is concerning.

Aim To establish the responses to the Sinopharm HB02 COVID‐19 vaccination in the dialysis population, which are not well established. We examined the humoral responses to the Sinopharm COVID vaccine in haemodialysis patients. Methods Standard vaccinations (two doses at interval of ~21 days) were given to all consenting haemodialysis patients on dialysis ( n = 1296). We measured the antibody responses at 14–21 days after the second vaccine to define the development of anti‐spike antibodies >15 AU/ml after vaccination and observed the clinical effects of vaccination. Results Vaccination was very well tolerated with few side‐effects. In those who consented to antibody measurements, ( n = 446) baseline sampling showed 77 had positive antibodies, yet received full vaccination without any apparent adverse events. Positive anti‐spike antibodies developed in 50% of the 270 baseline negative patients who had full sampling, compared with 78.1% in the general population. COVID infection continues to occur in both vaccinated and unvaccinated individuals, but in the whole group vaccination appears to have been associated with a reduction in the case fatality rate. Conclusion The humoral immune responses to standard HB02 vaccination schedules are attenuated in a haemodialysis cohort, but likely the vaccine saves lives. We suggest that an enhanced HB02 vaccination course or antibody checking may be prudent to protect this vulnerable group of patients. We suggest a booster dose of this vaccine at 3 months should be given to all dialysis patients, on the grounds that it is well tolerated even in those with good antibody levels and there may be a survival advantage.

Background: End stage kidney disease patients on maintenance dialysis are vulnerable to contract COVID-19 infection and variable degrees of disease severity have been reported. SEHA Kidney Care (SKC) is the largest provider of dialysis services in the United Arab Emirates providing dialysis services to ~1180 patients, including ~80 patients on peritoneal dialysis. Mortality of COVID-19 among patients with ESKD on dialysis is high and ranges from 14 to 31% in different published series. Not much is known about antibody response to COVID-19 in this group of patients. Patient population demographics in the UAE are dissimilar to many other countries. The objective of this study was to describe the characteristics of patients and clinical staff who developed COVID-19 RT-PCR positivity and assess antibody response to COVID-19.Methods: We conducted a retrospective analysis to characterize features of COVID-19 in our adult dialysis population. In addition, IgG antibody serology was also performed to assess response to COVID-19. Results: The incidence of COVID-19 infection in our population was 13%. 81% of the patients were males, average age was 53.2 ± 12​ years, and 95% were on in-center haemodialysis. The majority of patients (68%) developed mild disease while 13% required critical care. Combinations of drugs including Hydroxychloroquine, Favipiravir, Lopinavir, Ritonavir, Camostat, Tocilizumab and steroids were used based on local guidelines. The median time to viral clearance was 15 days [IQR 6-26]. Overall mortality in our cohort was 9.2%.We performed COVID-19 IgG antibody serology in a subset (n=87) of RT-PCR positive patients. Interestingly, 23 (26%) patients did not develop any antibody response. We successfully implemented a regular screening strategy for patients and staff to identify asymptomatic carriers with an aim to isolate them from the rest of the cohort.Conclusions: Our study has highlighted an important finding of lack of antibody response in a quarter of patients with ESKD. This may have significant implications for this group of patients while efforts are underway to develop an effective vaccine against COVID-19. With regular screening of all dialysis patients and staff, asymptomatic carriers can be identified and prevent spread of COVID-19 within the dialysis units.

No abstract

CKD 5 underwent hemodialysis post CABG. AKI had a significant correlation with prolonged ICU stay of more than 48 hours (p value 0.021).Amongst the 191 patients, percentage of patients having AKI with recent myocardial infarction of less than 90 days pre CABG, was higher (38.6%) as compared to those without AKI(25.9%). Percentage of patients developing AKI with diastolic dysfunction and LVEF <35% was greater (72% and 13.6%) as compared to those not developing AKI (60% and 8.2%). Patients developing AKI with infections and arrhythmias post CABG were more (15.9% and 29.5%) as compared to those not developing AKI with infections and arrhythmias. (7.4%and 19%)- Table 3. 6 patients were operated on pump while 185 had beating heart(off pump) surgeries. 3/6(50%) patients on pump had AKI, while 41/185 (22%) off pump patients had AKI. Amongst the CKD group, only 2 patients had on pump surgery and both developed AKI (100%) while off pump 36/70 (51%) had AKI.In the CKD cohort, increased incidence of AKI was observed with the following risk factors as compared to non CKD patients with similar risk factors : Infection(57.1%), bleeding(50%), diabetes mellitus (DM) (55.3%), Shock(33.3%), post op arrhythmias(52.9%), recent MI(less than 90 days pre CABG(59.2%), LV EF<35% (62.5%) and diastolic dysfunction (57.4%)- Table 4. Conclusions: Post CABG CKD patients are at a higher risk of per operative AKI as compared to those without CKD. The chances of AKI are more with worsening CKD Stage. Patients with diastolic dysfunction, EF less than 35% and recent MI<90 days pre CABG are at a high risk of developing AKI. Post op arrhythmias and infections in the ICU are important precipitating factors for AKI post CABG. POSTER SESSION: EPIDEMIOLOGY, OUTCOMES AND HEALTH SERVICES RESEARCH IN DIALYSIS -1 (MODERATED)Introduction: Worldwide, home haemodialysis (HHD) has been advocated mainly for independent and relatively healthy dialysis patients; however, this is not the practice locally. The number of dialysis patients with multi comorbidities, debilitated, bed and home bound has largely increased leading to a significant burden on the active hospital beds, on the outpatient dialysis units and on health care providers as well. Nurse assisted home haemodialysis (NAHHD) is thus introduced to overcome this problem. We present our one-year outcome with (NAHHD) both at home and in long-term care facilities. Methods: Haemodialysis patients who were fulfilling the National Insurance Company criteria for HHD were accepted in the (NAHHD) programme. These criteria include mainly frail, disabled, bed and home bound patients requiring special transportation from their home to the dialysis unit. Our portable dialysis machine is used to deliver haemodialysis therapy at patient home or at long term care facilities by well experienced haemodialysis nurses. Dialysate solution volume, length and weekly number of the dialysis sessions were calculated by dose calculator with a targeted weekly std Kt/V of $ 2. Patients who were on this modality for at least three mont...